Back

Comparative cost-effectiveness of atrial fibrillation ablation versus pharmacological therapy.

20 June 2017 (14:00 - 14:22)
Organised by:
Congress Presentation Part of: Is it worth the money? Cost-effectiveness in electrophysiology Policy initiative EHRA Premium Access EHRA EUROPACE - CARDIOSTIM 2017

About the speaker

Photo
Doctor Jane Cochrane Caldwell

Hull and East Yorkshire Hospitals NHS Trust, Hull (United Kingdom of Great Britain & Northern Ireland)

3 More presentations in this session

Presentation thumbnail
Patient compliance and outcomes of pharmacological therapy and atrial fibrillation ablation.
Professor S. Saksena (Warren, US)
Slides Video
Presentation thumbnail
Commissioning and reimbursement of atrial fibrillation ablation in Europe.
Professor F. Braunschweig (Stockholm, SE)
Presentation thumbnail
The role of the ESC Health Policy: relevance to electrophysiology and cardiac device practice.
Professor P. Vardas (Heraklion, GR)
Slides Video

Access the full session

Session thumbnail
Is it worth the money? Cost-effectiveness in electrophysiology

The Event

Event poster

EHRA EUROPACE - CARDIOSTIM 2017

20 June 2017 14:00 CET
You may be interested in
thumbnail
Congress Presentation
Decision-analytic modeling of concomittant left atrial appendage closure versus lifelong anticoagulation after atrial fibrillation ablation: cost-effectiveness and lifetime outcomes
12 April 2026
thumbnail
Congress Session
Novel arrhythmia treatments
24 June 2023
thumbnail
Congress Presentation
A cost-consequence analysis comparing three distinct cardiac ablation strategies for the treatment of paroxysmal atrial fibrillation
1 September 2024
thumbnail
Congress Presentation
1 September 2019

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources